PE-22-28

PE-22-28 is a synthetic peptide analog of spadin, an endogenous peptide derived from the protein sortilin. It has been investigated in preclinical research as a candidate for rapid-onset antidepressant effects, a property that has drawn interest because conventional antidepressants often take weeks to act.

PE-22-28 is investigational and animal-stage. It is not an approved medicine in any jurisdiction, and the descriptions below reflect exploratory laboratory work rather than validated clinical outcomes.

The central hypothesis behind PE-22-28 concerns the TREK-1 (KCNK2) potassium channel, which has been linked in animal models to mood regulation. High-level mechanistic themes include:

• Blocking or inhibiting the TREK-1 background potassium channel

• Modulating neuronal excitability in brain regions associated with mood, in a way researchers hypothesize could support neuroplasticity

• Acting more quickly than pathways targeted by traditional monoamine drugs

Whether these preclinical mechanistic observations translate into meaningful, reproducible effects in humans is entirely unestablished and remains a research question.

PE-22-28 has no approved therapeutic indication. It appears in the scientific literature as a research tool and antidepressant candidate studied in rodent models, not as a treatment for depression or any other condition in people.

Because it is investigational, any appearance of PE-22-28 in a catalog or research setting should be understood as reference material tied to early-stage neuroscience, not as an available or validated therapy.

PE-22-28 is not a recognized performance-enhancing agent, and it is not individually named on WADA prohibited lists. However, WADA category S0 covers any pharmacological substance not addressed by other sections and with no current approval for human therapeutic use. An investigational, non-approved peptide such as PE-22-28 would therefore be treated as prohibited at all times under that catch-all provision.

There are no notable publicized doping cases associated with PE-22-28, which is consistent with its status as an early-stage laboratory compound.

Because the compound has not undergone formal human safety evaluation, its side effect profile in people is unknown. General considerations that apply to investigational peptides include uncertainty about off-target effects, unknown long-term consequences, and product quality risks outside regulated frameworks.

The absence of documented harms is not evidence of safety; it reflects the very limited scope of study. Rigorous safety characterization has not been performed.

PE-22-28 is a modified analog of spadin engineered in laboratory studies to improve properties such as stability relative to the parent peptide. Its pharmacology has been explored in animal models rather than in defined human pharmacokinetic studies.

This information summarizes how the compound is described in preclinical research and does not constitute medical advice or a usage recommendation.

In research settings, spadin analogs such as PE-22-28 are typically handled as lyophilized powders for reconstitution. It may be grouped conceptually alongside other neuroscience-oriented research peptides.

Any structural listing in this catalog is organizational and should not be read as an endorsement of specific combinations, regimens, or use cases.

The evidence base for PE-22-28 consists mainly of preclinical neuroscience studies exploring TREK-1 inhibition and rapid antidepressant-like effects in animal models. This work has generated mechanistic interest but has not advanced to established human clinical trials.

Because the literature is early-stage and narrow, claims that PE-22-28 treats depression in humans go well beyond what the evidence supports. High-level summaries are not a substitute for critical appraisal of the primary research.

For deeper dives on this peptide, see:

• PE-22-28 areas of research interest
• PE-22-28 side effects and safety context
• PE-22-28 pharmacology concepts (educational)
• PE-22-28 research and evidence overview

Future FAQs may cover high-level questions such as how PE-22-28 relates conceptually to spadin and the TREK-1 channel, why fast-acting antidepressant mechanisms attract research interest, and how scientists distinguish promising animal findings from established human treatments. Answers will remain educational and non-prescriptive.